Pharmacopeia Inc

Pharmacopeia — BIO CEO & Investor Conference 2008

34 slides from Pharmacopeia's conference presentation, Feb 11, 2008

  1. Slide 1: Discovering excellence, driving clinical success

    Slide 1: Discovering excellence, driving clinical success

    Discovering excellence, driving clinical successTM Leslie J. Browne, Ph.D. President & CEO BIO CEO & INVESTOR CONFERENCE 2008 New York City February 12th, 2008

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements . This presentation, and oral statements made with respect to information contained in this presentation, constitute forwardlooking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which ex

  3. Slide 3: Achieving Development Milestones

    Slide 3: Achieving Development Milestones

    Achieving Development Milestones First-in-class DARA – Phase 2 Proof of Concept results in 2Q-08 Potential best-in-class SARM – MAD study in 2H-08 – Phase 2 POC study in 1H-09 CCR1 program in development – IND-enabling studies underway Partners’ results upcoming – CXCR2 antagonist in Phase 2 – p38 k

  4. Slide 4: Agenda for Today

    Slide 4: Agenda for Today

    Agenda for Today Pharmacopeia Transformed Strong internal portfolio – 1 program in Phase 2 - DARA – 1 program in Phase 1 – SARM – 1 program in preclinical dev – CCR1 Strong partnered portfolio – 2 programs in Phase 2 • CXCR2 antagonist with Schering-Plough • p38 kinase inhibitors with BMS • 3 progra

  5. Slide 5: Strong Internal Portfolio

    Slide 5: Strong Internal Portfolio

    Rheumatoid Arthritis CCR1 antagonist PS031291 Muscle Wasting SARM PS178990 Cardiovascular DARA PS433540 Parkinson’s Adenosine A2A Topical Psoriasis JAK3 NDA Filed 3 2 I Dev elopment Optimization Lead Generation Program Clinical Phase Preclinical Strong Internal Portfolio 2 programs in clinical devel

  6. Slide 6: Agenda for Today

    Slide 6: Agenda for Today

    Agenda for Today Pharmacopeia Transformed Strong internal portfolio – 1 program in Phase 2 - DARA – 1 program in Phase 1 – SARM – 1 program in preclinical dev – CCR1 Strong partnered portfolio – 2 programs in Phase 2 • CXCR2 antagonist with Schering-Plough • p38 kinase inhibitors with BMS • 3 progra

  7. Slide 7: PS433540 (DARA)

    Slide 7: PS433540 (DARA)

    PS433540 (DARA) – First-in-class DARA combines the properties of two marketed product classes – Potential for blood pressure control and kidney protection Efficacy, Safety, Compliance advantages for dual mechanism – Potent blood pressure lowering in multiple hypertension models – Dual approach valid

  8. Slide 8: Hypertension and Diabetic Nephropathy

    Slide 8: Hypertension and Diabetic Nephropathy

    Hypertension and Diabetic Nephropathy Growing patient population of hypertensives and diabetics • 50-60% of patients do not achieve blood pressure goals • Most patients require 2 or more drugs to achieve control • 20-40% of diabetics progress to kidney disease Current treatment of kidney disease uns

  9. Slide 9: Dose Dependent Angiotensin II Blockade

    Slide 9: Dose Dependent Angiotensin II Blockade

    Dose Dependent Angiotensin II Blockade • All differences vs placebo statistically significant • Inhibits AII response at all doses to 24h • Full blockade with 250, 500 mg at least as effective as 300mg irbesartan

  10. Slide 10: Confirmation of AII blockade from MAD study

    Slide 10: Confirmation of AII blockade from MAD study

    -20 -15 -10 -5 0 Confirmation of AII blockade from MAD study 0 10 20 30 Placebo 100 mg 250 mg 500 mg 1000 mg Mean Change from Baseline ng/mL/hr Mean Change from Baseline mmHg Change in Plasma Renin Activity Day 15; 8 hours post-dose Change in Systolic Blood Pressure Day 15; 8 hours post-dose * * *P<

  11. Slide 11: Results from Clinical Development

    Slide 11: Results from Clinical Development

    Results from Clinical Development Safe and well tolerated to date – 2 weeks oral dosing up to 1000 mg – 4 weeks oral dosing at 200 and 500 mg – exposure in >100 subjects so far Excellent pharmacokinetic profile – Once-a-day oral dosing – Rapid absorption, 24 hour duration of activity Activity in nor

  12. Slide 12: Agenda for Today

    Slide 12: Agenda for Today

    Agenda for Today Pharmacopeia Transformed Strong internal portfolio – 1 program in Phase 2 - DARA – 1 program in Phase 1 – SARM – 1 program in preclinical dev – CCR1 Strong partnered portfolio – 2 programs in Phase 2 • CXCR2 antagonist with Schering-Plough • p38 kinase inhibitors with BMS • 3 progra

  13. Slide 13: Potential Benefits of SARM

    Slide 13: Potential Benefits of SARM

    7 Muscle Mass 7 Muscle Strength Potential Benefits + Cognition tT Energy T Libido A 7 Bone Formation | Bone Resorption 7 Bone Density & Strength

  14. Slide 14: Effects To Be Minimized

    Slide 14: Effects To Be Minimized

    Effects To Be Minimized — Pharmacopeia Effects of Androgens Potential Risks Bone Marrow T Red Cell Production + Sebum Production + Hair Growth + Prostate Mass 1 Cell Turnover

  15. Slide 15: SARM: Medical Need

    Slide 15: SARM: Medical Need

    BMS-564929 N N H O CN HO O Cl SARM: Medical Need – are orally active, non-steroidal small molecules – improve muscle mass and function – have minimal effects on the prostate, gonadotropin levels, hematopoiesis PS178990 ED50 levator = 0.9 µg/kg ED50 prostate = 141 µg/kg selectivity = 160-fold In prec

  16. Slide 16: Opportunities For SARM

    Slide 16: Opportunities For SARM

    Opportunities For SARM $3,500 $5,000 $6,000 10,000 17,000 19,000 Osteoporosis – Bone Loss Sarcopenia – Muscle Loss Frailty – Osteoporosis and Sarcopenia Aging - related $400 $500 $2,000 $800 $1,000 40 320 400 900 8,750 Burn Victims End Stage Renal Disease Cancer AIDS Surgery, Trauma & Burn Recovery

  17. Slide 17: What we know so far

    Slide 17: What we know so far

    What we know so far Safe and well tolerated in SAD – Single oral dose from 0.003 – 2.0 mg Pharmacokinetic profile in man – Kinetics consistent with once-a-day oral dosing – Rapid absorption, 24 hour duration of activity Pre-clinical activity – 200x more potent than testosterone in muscle – 160-fold

  18. Slide 18: SARM - Development Plans

    Slide 18: SARM - Development Plans

    SARM - Development Plans Complete technology transfer – 1Q-08 Qualify API – 6 kg available Initiate Multiple Ascending Dose study – 2H-08 Initiate Phase 2 – 1H-09 – Effects on lean body mass, muscle strength and prostate in relatively healthy elderly men – 6 months • lean body mass; functional perfo

  19. Slide 19: Agenda for Today

    Slide 19: Agenda for Today

    Agenda for Today Pharmacopeia Transformed Strong internal portfolio – 1 program in Phase 2 - DARA – 1 program in Phase 1 – SARM – 1 program in preclinical dev – CCR1 Strong partnered portfolio – 2 programs in Phase 2 • CXCR2 antagonist with Schering-Plough • p38 kinase inhibitors with BMS • 3 progra

  20. Slide 20: CCR1 Antagonist Rationale

    Slide 20: CCR1 Antagonist Rationale

    20 CCR1 Antagonist Rationale CCR1 expressed on cells of cells of the immune system including monocytes, T cells, dendritic cells, eosinophils and neutrophils CCR1 - major factor in mediating inflammatory responses through direct effects on leukocyte chemotaxis and Th1/Th2 cytokine balance Multiple i

  21. Slide 21: Significant Market Opportunity

    Slide 21: Significant Market Opportunity

    Significant Market Opportunity RA is large market - forecast to be $10 billion in 2016 The global RA market forecast split by biologic and traditional market and small molecule pipeline sales, $, m, 2007-2016 - 2,000 4,000 6,000 8,000 10,000 12,000 2007 2008 2009 2010 2011 2012 2013 2014 2015 201 6

  22. Slide 22: PS031291 - Potentially Best-in-Class

    Slide 22: PS031291 - Potentially Best-in-Class

    -10 -9 -8 -7 -6 -5 0 10 20 30 40 50 60 70 80 90 100 No compound 12nM PS031291 34nM PS031291 100nM PS031291 log [MIP-1a] (M) %CCR1 internalization PS031291- Potentially Best-in-Class Best of the Rest PS031291 -10 -9 -8 -7 -6 -5 0 10 20 30 40 50 60 70 80 90 100 100nM MLN-3897 50nM MLN-3897 25nM MLN-38

  23. Slide 23: Small Molecule Opportunity

    Slide 23: Small Molecule Opportunity

    Small Molecule Opportunity • Significant interest in novel small molecules – JAK3 kinase inhibitors (Pfizer Ph2; Rigel Ph1; WYE/Pharmacopeia PC) – P38 MAP kinase inhibitors (BMS/Pharmacopeia Ph2) – CCR1 antagonists (Chemocentryx/GSK Ph1) – SYK kinase inhibitors (Rigel Ph2) • High prevalence disease

  24. Slide 24: Agenda for Today

    Slide 24: Agenda for Today

    Agenda for Today Pharmacopeia Transformed Strong internal portfolio – 1 program in Phase 2 - DARA – 1 program in Phase 1 – SARM – 1 program in preclinical dev – CCR1 Strong partnered portfolio – 2 programs in Phase 2 • CXCR2 antagonist with Schering-Plough • p38 kinase inhibitors with BMS • 3 progra

  25. Slide 25: Strong Partnered Portfolio

    Slide 25: Strong Partnered Portfolio

    Immuno/Inflam JAK3 Inflammation PS873266 Undisclosed PS015146 Metabolic Disease PS248288 Respiratory PS948115 Inflammation PS386113 Oncology PS095760 Psoriasis/RA p38 MAP kinase PS540446 COPD CXCR2 PS291822 NDA Filed 3 2 I Dev elopment Optimization Lead Generation Program Clinical Phase Preclinical

  26. Slide 26: Potential New Rx for COPD

    Slide 26: Potential New Rx for COPD

    Potential New Rx for COPD Large Market Potential – CXCR2 antagonist blocks neutrophil recruitment to the lung – Therapeutic target is COPD - chronic bronchitis and emphysema – $9B and 14MM patients in the US alone Program Status – CXCR2 antagonist in Phase 2 COPD study • Active against biomarker at

  27. Slide 27: CXCR2 Blockers for Lung Disease

    Slide 27: CXCR2 Blockers for Lung Disease

    CXCR2 Blockers for Lung Disease Phase 2a study to evaluate efficacy, safety and PK in moderate to severe chronic obstructive pulmonary disease – 590 patients, smokers 40-75 years old with COPD – Improvements in FEV-1, sputum production, dyspnea, cough – 2 part study each with 2 week run-in and 12 we

  28. Slide 28: Novel Orally Available Rx for Inflammation

    Slide 28: Novel Orally Available Rx for Inflammation

    Novel Orally Available Rx for Inflammation Large Market Potential – Block release of TNFa and IL-1 – Combines the effects of Enbrel and Kineret – Expected utility in RA, COPD, Psoriasis & IBD • RA – $5.6B and 2.1MM patients in the US alone Program Status – p38 kinase inhibitor, PS540466, in Phase 2

  29. Slide 29: p38 Kinase Inhibitors for Inflammation

    Slide 29: p38 Kinase Inhibitors for Inflammation

    p38 Kinase Inhibitors for Inflammation Phase 2 studies to evaluate efficacy, safety and PK in: 1. Moderate to severe plaque psoriasis ~100 patients, 12 wks, PASI-50, started 3Q-07 2. Rheumatoid arthritis with methotrexate ~120 patients, 12 wks, ACR-20,50,70, start 1Q/08 3. Atherosclerosis vs. 80 mg

  30. Slide 30: Agenda for Today

    Slide 30: Agenda for Today

    Agenda for Today Pharmacopeia Transformed Strong internal portfolio – 1 program in Phase 2 - DARA – 1 program in Phase 1 – SARM – 1 program in preclinical dev – CCR1 Strong partnered portfolio – 2 programs in Phase 2 • CXCR2 antagonist with Schering-Plough • p38 kinase inhibitors with BMS • 3 progra

  31. Slide 31: Financial Summary

    Slide 31: Financial Summary

    Financial Summary For the 9 Months Ended September 30, 2007 $16.4 million in net revenue $28.6 million in net loss Cash, Cash Equivalents and Marketable Securities $81.4 million as of September 30, 2007 December 31, 2007 ending cash balance expected to be $65 - 70 million

  32. Slide 32: Clinical Pipeline Progress

    Slide 32: Clinical Pipeline Progress

    Respiratory PS948115 SARM PS178990 DARA PS433540 Inflammation PS386113 Oncology PS095760 Psoriasis/RA p38 MAP kinase PS540446 COPD/CXCR2 PS291822 3 2 I Dev elopment Optimization Program Clinical Phase Preclinical Clinical Pipeline Progress Denotes clinical progress since March 2007

  33. Slide 33: News Flow in 2008 - 2009

    Slide 33: News Flow in 2008 - 2009

    News Flow in 2008 - 2009 2H:08 DARA: Endothelin challenge study initiated SARM: Initiate Phase 1 MAD study DARA: Phase 2a Proof of Concept study results DARA: 2nd Phase 2 hypertension study initiated 1H:08 1H:09 SARM: Initiate Phase 2 DARA: Endothelin challenge results DARA: 2nd Ph 2 hypertension re

  34. Slide 34: Discovering excellence, driving clinical success

    Slide 34: Discovering excellence, driving clinical success

    Discovering excellence, driving clinical successTM Leslie J. Browne, Ph.D. President & CEO BIO CEO & INVESTOR CONFERENCE 2008 New York City February 12th, 2008

Source: SEC EDGAR · 8-K filed Feb 11, 2008

More decks from Pharmacopeia Inc